CROI 2013: Functional Cure of HIV-infected Infant after Early ART [VIDEO]
The big news on the opening day of the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) was a report about an infant with HIV who started combination antiretroviral treatment very early and now shows no evidence of replication-competent virus. "We equate this to our Berlin Patient," said Deborah Persaud from Johns Hopkins University School of Medicine. "It could get us on the road to a cure for HIV-infected children."
Coverage of the 2012 AASLD Liver Meeting
HIVandHepatitis.com coverage of the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012) in Boston, November 9-13, 2012.
Conference highlights include treatment for hepatitis B and C, new direct-acting HCV drugs, interferon-free hepatitis C therapy, management of liver disease complications, HIV/HBV and HIV/HCV coinfection, and prevention and treatment of hepatocellular carcioma.
HIVandHepatitis.com AASLD 2012 conference section

Some Men Shed HIV in Semen Despite ART, Linked to Herpesvirus Coinfection
About 10% of gay men in a U.S. study had detectable HIV in their semen despite suppression of blood plasma viral load with antiretroviral therapy (ART), which has implications for HIV transmission, according to a study described in the April 17, 2013, advance online edition of Clinical Infectious Diseases. Having a low but detectable blood viral load and coinfection with cytomegalovirus or Epstein-Barr virus were associated with increased likelihood of semen HIV shedding.

DDW 2013: Simeprevir Boosts Response to Interferon-based Therapy for Prior Relapsers
Adding the HCV protease inhibitor simeprevir (formerly TMC435) to pegylated interferon and ribavirin cured 79% of prior relapsers, and most were eligible to complete treatment after 3 months, according to findings from the PROMISE study presented at the Digestive Disease Week meeting (DDW 2013) this week in Orlando.


















